Holland & Knight Advises Venture Life Group on $28 Million Acquisition of FemiClear and CUROXEN from OrganiCare Nature’s Sciences

NEW YORK (June 3, 2026) – Holland & Knight represented Venture Life Group (AIM: VLG), a United Kingdom-based consumer self-care company focused on proactive healthy longevity, in its acquisition of FemiClear and CUROXEN from U.S.-based OrganiCare Nature's Sciences, for up to $28 million. The transaction was announced on June 3.

OrganiCare focuses on providing natural, clinically effective alternative pharmaceuticals. The acquisition establishes a scaled presence for Venture Life in the U.S. women's intimate health market, expands the company's product offering into high-growth gynecological treatment categories and provides access to a $700 million U.S. feminine treatment retail opportunity.

Venture Life has a core portfolio of high-growth, high-margin products that promote and support consumers' goals of maintaining health and longevity.

Holland & Knight Partners William Weiner and Nili Yolin (Healthcare Transactions) led the Firm's representation of Venture Life. They were assisted by Partner Rachel Gartner (FDA Regulatory) and Associates Emily Kaiser and Henry Booth (Corporate M&A).

More information on the transaction can be found here.

Recently recognized as the Private Equity Law Firm of the Year by the Global M&A Network and M&A Law Firm of the Year by M&A Advisor, Holland & Knight regularly ranks among the leading M&A and private equity law firms in reputable, benchmarking league tables published by Bloomberg, LSEG, Mergermarket, PitchBook and The Deal. Through the HK Deal Flow℠ program, Holland & Knight facilitates deal leads for clients and prospective clients by matching acquisition or capital raising opportunities with buyers and investors.